McKay Samuel F

Avg. Two Year Performance

No purchase track record
(2%) Avg. Sale Return
(1%) Compound
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return----------
Purchase Success Rate----------
Average Sale Return< 1%(1%)(5%)(2%)(2%)
Sale Success Rate2 of 52 of 52 of 52 of 50 of 5

Anika Therapeutics Inc.

Drugs » Biotechnology

Director:

Holdings: 0 shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--